ENZ Stock Overview
A life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Enzo Biochem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.97 |
| 52 Week High | US$1.50 |
| 52 Week Low | US$0.97 |
| Beta | 0.73 |
| 11 Month Change | -16.38% |
| 3 Month Change | -14.91% |
| 1 Year Change | -21.14% |
| 33 Year Change | -70.96% |
| 5 Year Change | -64.34% |
| Change since IPO | -94.76% |
Recent News & Updates
Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?
Nov 19
Enzo Biochem: Is This Time Finally Different?
Jul 17Recent updates
Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?
Nov 19Enzo Biochem: Is This Time Finally Different?
Jul 17Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Oct 26Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?
May 18Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Jan 03Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M
Dec 12Enzo Biochem appoints Patricia Eckert as interim CFO
Oct 20Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M
Oct 14Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Oct 04Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale
Jun 27Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?
May 03Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Dec 17Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?
Aug 24Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Mar 01Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?
Feb 03If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%
Jan 08
Enzo Biochem nabs expanded EUA nod for testing of COVID samples
Jan 04Enzo Biochem: Betting On The Activists Now
Dec 16Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay
Dec 13Shareholder Returns
| ENZ | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -14.9% | -1.2% | -1.0% |
| 1Y | -21.1% | 2.5% | 30.3% |
Return vs Industry: ENZ underperformed the US Healthcare industry which returned 2.5% over the past year.
Return vs Market: ENZ underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| ENZ volatility | |
|---|---|
| ENZ Average Weekly Movement | 4.1% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENZ has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 131 | Kara Cannon | www.enzo.com |
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
Enzo Biochem, Inc. Fundamentals Summary
| ENZ fundamental statistics | |
|---|---|
| Market cap | US$51.57m |
| Earnings (TTM) | -US$9.82m |
| Revenue (TTM) | US$31.91m |
1.6x
P/S Ratio-5.2x
P/E RatioIs ENZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENZ income statement (TTM) | |
|---|---|
| Revenue | US$31.91m |
| Cost of Revenue | US$17.28m |
| Gross Profit | US$14.63m |
| Other Expenses | US$24.45m |
| Earnings | -US$9.82m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 45.86% |
| Net Profit Margin | -30.77% |
| Debt/Equity Ratio | 0.5% |
How did ENZ perform over the long term?
See historical performance and comparisonDividends
41.2%
Current Dividend Yieldn/a
Payout RatioDoes ENZ pay a reliable dividends?
See ENZ dividend history and benchmarks| Enzo Biochem dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Dec 02 2024 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 10 days |
Does ENZ pay a reliable dividends?
See ENZ dividend history and benchmarks